Table 3.
Markers of late cardiac and skin adverse events of breast cancer therapy and treatment outcome.
| Marker | Category | N (%) | |
|---|---|---|---|
| Cardiac adverse events markers | NT-proBNP | <125 ng/L | 65 (64.4) |
| ≥125 ng/L | 36 (35.6) | ||
| NYHA | Class 1 | 84 (83.2) | |
| Class 2 | 17 (16.8) | ||
| LVEF reduction | No | 92 (91.1) | |
| Yes | 9 (8.9) | ||
| Skin adverse events | LENT-SOMA | Grade 1 | 68 (67.3) |
| Grade 2 | 31 (30.7) | ||
| Grade 3 | 2 (2.0) | ||
| CTCAE v.3 | Grade 1 | 89 (88.1) | |
| Grade 2 | 12 (11.9) | ||
| Treatment outcome | Disease recurrence | No | 98 (97.0) |
| Yes | 3 (3.0) | ||
| New primary tumor | No | 92 (91.1) | |
| Yes | 9 (8.9) | ||
| Death | No | 99 (98.0) | |
| Yes | 2 (2.0) |
CTCAE v.3., Common Terminology Criteria for Adverse Events, version 3.0; LENT SOMA, Late Effects in Normal Tissues/Subjective, Objective, Management and Analytic; LVEF, left ventricular ejection fraction, NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA: New York Heart Association.